Study in Patients With Solid Tumor Regarding Access to Dermo-cosmetics and Aesthetic Solutions

Study Overview
=================
Brief Summary
-----------------
Cancer treatments can trigger cutaneous side-effects, as well as nail and hair toxicities. When related to drug treatment, this iatrogeny depends on the type of drug, its dosage and individual susceptibility. Although these dermatological adverse events are rarely serious, they can significantly alter patients' quality of life, and may even necessitate the introduction of curative treatment. The impact of these side effects can be mitigated by the use of dermo-cosmetic products and aesthetic solutions. However, most of this supportive care is not reimbursed by the health insurance system, representing a source of inequalities in access to healthcare for cancer patients.

Detailed Description
-----------------
This study aims at establishing, in a cohort of patients with solid tumors, the state of their knowledges, given information and their financial capacities regarding access to dermo-cosmetics and aesthetic solutions, that are used in the attenuation of cancer treatments' side-effects.

Official Title
-----------------
Study in Patients With Solid Tumor Regarding Access to Dermo-cosmetics and Aesthetic Solutions

Conditions
-----------------
Neoplasms

Intervention / Treatment
-----------------
* Other: Questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Patients with solid tumors (eligible localization include: digestive system, Head and Neck, Breast, Brain, Lung Tumors, Urological and Gynecologic cancers) Patients able to read and understand French Patients that has expressed their consent and with signed consent form Exclusion Criteria: Minor or patients placed under guardianship or supervision Patients unable to read French Patients placed under judicial protection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with Digestive System Cancer<br> | Other: Questionnaires<br>* 25-items questionnaire<br>|
| Patients with Head and Neck Cancer<br> | Other: Questionnaires<br>* 25-items questionnaire<br>|
| Patients with Breast Cancer<br> | Other: Questionnaires<br>* 25-items questionnaire<br>|
| Patients with Nervous System Tumors<br> | Other: Questionnaires<br>* 25-items questionnaire<br>|
| Patients with Urological Cancer<br> | Other: Questionnaires<br>* 25-items questionnaire<br>|
| Patients with Lung Cancer<br> | Other: Questionnaires<br>* 25-items questionnaire<br>|
| Patients with Gynecologic Cancer<br> | Other: Questionnaires<br>* 25-items questionnaire<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Describe patients' knowledges regarding cutaneous side-effects, nail and hair toxicities induced by anticancer drugs | 4 items questionnaires | at inclusion | 
| Describe patients' knowledges regarding dermo-cosmetics and aesthetic solutions that can attenuate cutaneous side-effects, nail and hair toxicities induced by anticancer drugs | 10 items questionnaires | at inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Describe patients' socio-economic profile to assess equity regarding access to dermo-cosmetics and aesthetic solutions | 11 items questionnaires | at inclusion | 
| Correlate patients' knowledge level depending on tumoral location | Tumoral location as described in medical chart | at inclusion | 
| Correlate patients' knowledge level depending on received treatment | Type of chemotherapy administered on the day of inclusion as described in medical chart | at inclusion | 
| Correlate patients' knowledge level depending on treatment phase | Type of treatment phase (i.e. neoadjuvant, adjuvant, 1st or 2nd metastatic line) as described in medical chart | at inclusion |